정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1038 | Recruiting | Methylprednisolone vs. Dexamethasone in COVID-19 Pneumonia (MEDEAS RCT) | Severe Acute Respiratory Syndrome | Drug: Methylprednisolone Drug: Dexamethasone |
Phase 3 | University of Trieste, Centro di Riferimento Oncologico - Aviano, National Institute for the Infectious Diseases (L. Spallanzani) - Rome | OTHER | 680 | All | 18 Years | Marco Confalonieri, Trieste, TS, Italy |
| 1037 | Suspended | Microbiome Therapy in Covid-19 Primary Care Support | Corona Virus Infection | Biological: Microbiome spray Biological: Placebo spray |
Not Applicable | University Hospital, Antwerp | OTHER | 150 | All | 18 Years ~ 65 Years | Veronique Verhoeven, Antwerp, Belgium |
| 1036 | Active, not recruiting | Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic | Acute Stress Disorder | Drug: Sublingual Micro-Dose Ketamine | Phase 4 | Limbic Medical, Enovex Pharmacy | OTHER | 30 | All | 18 Years | Limbic Medical, Toluca Lake, California, United States |
| 1035 | Recruiting | Mineralocorticoid Receptor Antagonist and Pulmonary Fibrosis in COVID-19. | COVID-19 Pneumonia | Drug: Canrenoate Potassium Drug: Normal Saline |
Phase 4 | Pomeranian Medical University Szczecin | OTHER | 50 | All | 18 Years ~ 90 Years | Pomeranian Medical University, Szczecin, Poland |
| 1034 | Recruiting | MIS-C Comparative Effectiveness Study | Multisystem Inflammatory Syndrome-Children | Drug: Infliximab Drug: Anakinra Drug: Methylprednisolone |
Phase 3 | University of California, San Diego | OTHER | 180 | All | ~ 20 Years | Rady Children's Hospital, San Diego, California, United States |
| 1033 | Not yet recruiting | Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines in Mozambique | Covid19 | Biological: BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell) Biological: AZD1222 (replication-deficient Ad type 5 vector expressing full-length spike protein) |
Phase 2 | International Vaccine Institute, The Coalition for Epidemic Preparedness Innovations (CEPI), Instituto Nacional de Saude (INS), Mozambique, University of Antananarivo, International Centre for Diarrhoeal Disease Research, Bangladesh, Harvard University, Heidelberg University | OTHER | 360 | All | 18 Years ~ 65 Years | Centro de Investigacao e Treino em Saude da Polana Canico - Instituto Nacional de Saude, Maputo, Mozambique |
| 1032 | Recruiting | Mix and Match of the Second COVID-19 Vaccine Dose for Safety and Immunogenicity | COVID-19 | Biological: mRNA-1273 SARS-CoV-2 vaccine Biological: BNT162b2 Biological: ChAdOx1-S [recombinant] Other: 0, 28 day schedule Other: 0, 112 day schedule |
Phase 2 | Canadian Immunization Research Network, Canadian Center for Vaccinology, BC Children's Hospital Research Institute, Children's Hospital Research Institute of Manitoba, CHU de Quebec-Universite Laval, Ottawa Hospital Research Institute, Ontario Agency for Health Protection and Promotion, University of Toronto, Massachusetts General Hospital, Interior Health | NETWORK | 1200 | All | 18 Years ~ 99 Years | University of Alberta, Edmonton, Alberta, Canada Royal Inland Hospital, Kamloops, British Columbia, Canada Penticton Regional Hospital, Penticton, British Columbia, Canada BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada Canadian Center for Vaccinology, Halifax, Nova Scotia, Canada Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada CHU de Quebec, Universite Laval, Quebec City, Quebec, Canada |
